Maiti Rituparna, Jaida Jyothirmai, Israel P L John, Koyagura Narendar, Mukkisa Sruthi, Palani Anuradha
Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh, India.
J Pharmacol Pharmacother. 2011 Jul;2(3):150-7. doi: 10.4103/0976-500X.83278.
To compare the efficacy and safety of rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease (GERD).
A randomized, single-blinded, outdoor-based clinical study was conducted on 60 patients of mild-to-moderate erosive GERD. After baseline clinical assessment and investigations, rabeprazole (40 mg) was prescribed to 30 patients and esomeprazole (40 mg) to another 30 patients for 4 weeks. The efficacy variables were change in GERD symptom scoring, endoscopic findings, and Quality of Life in Reflux and Dyspepsia (QOLRAD) scoring over 4 weeks.
Heartburn, acid regurgitation, and overall GERD symptom scoring (P = 0.01) were significantly decreased with rabeprazole in comparison to esomeprazole. The comparative study of all five domains of the QOLARD questionnaire including overall scoring revealed a statistically significant improvement in the rabeprazole group. Endoscopic findings in the rabeprazole group showed an absolute improvement of 30% and relative improvement of 55% over esomeprazole. Both the drugs were well tolerated having no significant difference in the incidence of adverse effects.
Rabeprazole (40 mg) is a better choice for mild-to-moderate GERD compared with esomeprazole (40 mg) because of its better efficacy and safety profile.
比较雷贝拉唑和埃索美拉唑治疗轻至中度糜烂性胃食管反流病（GERD）的疗效和安全性。
对60例轻至中度糜烂性GERD患者进行了一项随机、单盲、户外临床研究。在进行基线临床评估和检查后，给30例患者开了雷贝拉唑（40毫克），给另外30例患者开了埃索美拉唑（40毫克），疗程为4周。疗效变量包括4周内GERD症状评分、内镜检查结果以及反流和消化不良生活质量（QOLRAD）评分的变化。
与埃索美拉唑相比，雷贝拉唑治疗烧心、反酸及GERD总体症状评分（P = 0.01）显著降低。对包括总体评分在内的QOLARD问卷所有五个领域的比较研究显示，雷贝拉唑组有统计学意义的改善。雷贝拉唑组的内镜检查结果显示，与埃索美拉唑相比，绝对改善率为30%，相对改善率为55%。两种药物耐受性良好，不良反应发生率无显著差异。
雷贝拉唑（40毫克）治疗轻至中度GERD比埃索美拉唑（40毫克）是更好的选择，因为其疗效和安全性更佳。
